Matthew Hammond

Bio

Professional summary

Matthew Hammond is a Partner at RA Capital Management, where he works on both public and private investments. He serves as a board director for Ambros Therapeutics and previously served on the boards of DTx Pharma, Emergence Therapeutics, Forge Biologics, and Jnana Therapeutics before their respective acquisitions. He also served as CFO and Director of Research Alliance Corp I before its merger with Point Biopharma.

Notable companies

Selected portfolio companies the partner has backed

Ambros TherapeuticsDTx PharmaEmergence TherapeuticsForge BiologicsJnana TherapeuticsPoint Biopharma

Background

Career, education, and skills

Career history

RA Capital ManagementPartnerPresent
Research Alliance Corp ICFO and Director

Education

University of GeorgiaBS in Environmental Health Science
University of ConnecticutPhD in Biomedical Science
University of ConnecticutMBA in Finance

Other partners at RA Capital Management

12 more profiles

View firm →

Abigail (Lauterbach) Schmitz

Senior Associate

RA Capital Management

TechAtlas senior associate evaluating biotech opportunities and competitive landscapes.

biotech diligencecompetitive landscapesportfolio strategyTechAtlastherapeutics

Adam Prince, MD

Senior Associate, Strategic Initiatives

RA Capital Management

RA Capital TechAtlas senior associate with cardiology and medical training.

biotech diligencecardiologyhealth innovationportfolio strategyTechAtlas

Alana MacDonald, Ph.D.

Senior Associate

RA Capital Management

Senior TechAtlas associate focused on biotech diligence, landscapes, and portfolio strategy.

biotechnologycompetitive landscapesportfolio strategyTechAtlastherapeutics

Alejandro Sevilla

Associate

RA Capital Management

Planetary Health associate focused on climate-tech landscapes and investment evaluation.

advanced batteriesclimate technologycompetitive landscapesenergy storageplanetary health

Alex Miller

Senior Associate, Venture

RA Capital Management

Venture senior associate focused on biotech diligence and portfolio strategy.

biotechnologyprogram strategyTechAtlastherapeuticsventure investing

Alex T. Zhang

Vice President, Structured Capital

RA Capital Management

Structured Capital VP focused on healthcare and life-sciences credit investments.

commercial-stage healthcarehealthcare creditlife sciencesprivate creditstructured capital

Alexander Martinez-Forte

Director, Quantitative Research & Strategy

RA Capital Management

RA Capital director leading quantitative analyses for investment decisions and portfolio management.

Data scienceFinancial riskHealthcare investingInvestment analyticsPortfolio managementQuantitative research

Allison Harrigan

Senior Director Corporate Development

RA Capital Management

Raven corporate development leader focused on biotech company creation.

Biotech strategyBusiness developmentCompany creationCorporate developmentDrug discovery

Alyssa Larson

Director, Healthcare Specialist - Investor Relations

RA Capital Management

TechAtlas director supporting healthcare diligence and investor relations.

BiochemistryCompetitive landscapesHealthcare diligenceInvestor relationsTechAtlas

Ami Thakrar, PhD

Associate

RA Capital Management

TechAtlas associate focused on biotech diligence and program strategy.

biotechnologycompetitive landscapesmedical engineeringprogram strategyTechAtlas

Anish K. More

Vice President, Corporate Development

RA Capital Management

Raven corporate-development VP focused on investment evaluation and NewCo creation.

company creationcorporate developmenthealthcare servicesNewCosRaven

Anurag Kondapalli

Principal

RA Capital Management

Principal investing across public and private healthcare technology and services companies.

healthcare serviceshealthcare technologyprivate investmentspublic investmentsstructured growth capital

See something out of date?

Suggest a correction — our team reviews every edit.

Improve this profile